Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ABBV | NYSE | USD | Real-time | |
0QCV | London | EUR | Real-time | |
ABBV | BIVA | MXN | Delayed | |
ABBV | Mexico | MXN | Delayed | |
1ABBV | Milan | EUR | Real-time | |
4AB | TradeGate | EUR | Delayed | |
4AB | Frankfurt | EUR | Delayed | |
ABBV34 | B3 | BRL | Delayed | |
ABBV | Vienna | EUR | Real-time |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | - | - | - | - | - |
Technical Indicators | - | - | - | - | - |
Summary | Neutral | Neutral | Neutral | Neutral | Neutral |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Engulfing Bearish | 1M | Current | |||
Completed Patterns | |||||
Bullish doji Star | 30 | 1 | Feb 24, 2022 20:30 | ||
Tri-Star Bullish | 15 | 1 | Feb 24, 2022 20:45 | ||
Bullish Engulfing | 5H | 2 | Feb 24, 2022 12:00 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
NYSE | 181.97 | 181.65 | 183.84 | 3,075,218 | +0.90% | USD | |||
London | 181.20 | 172.10 | 190.20 | 3,608 | +1.12% | EUR | |||
BIVA | 2,880.00 | 0.00 | 0.00 | 0 | 0.00% | MXN | |||
Mexico | 2,980.76 | 0.00 | 0.00 | 0 | 0.00% | MXN | |||
Milan | 165.00 | 0.00 | 0.00 | 0 | 0.00% | EUR | |||
TradeGate | 168.80 | 168.60 | 169.00 | 3,081 | +1.38% | EUR | |||
Frankfurt | 167.80 | 168.50 | 169.10 | 344 | +1.02% | EUR | |||
B3 | 57.01 | 55.92 | 57.75 | 746 | +1.95% | BRL | |||
Vienna | 164.70 | 161.00 | 164.70 | 0 | +0.00% | EUR |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
IAG | 176.75 | 177.70 | 170.95 | +5.25 | +3.06% | 34.56M | 28/03 | ||
Rolls-Royce Holdings | 426.70 | 430.50 | 411.40 | +4.70 | +1.11% | 16.81M | 28/03 | ||
Lloyds Banking | 51.76 | 52.54 | 51.57 | +0.09 | +0.17% | 157.24M | 28/03 | ||
Barclays | 183.20 | 185.74 | 182.82 | +1.68 | +0.93% | 48.73M | |||
JD Sports Fashion | 134.50 | 136.75 | 114.86 | +18.20 | +15.65% | 61.63M | 28/03 | ||
Vodafone Group PLC | 70.460 | 70.720 | 69.700 | +1.040 | +1.50% | 65.30M | 28/03 | ||
Avacta Group | 49.75 | 50.00 | 48.40 | +0.75 | +1.53% | 3.37M | 28/03 | ||
M&G | 220.50 | 233.55 | 219.80 | -14.30 | -6.09% | 9.42M | 28/03 | ||
EasyJet | 570.80 | 572.80 | 556.40 | +13.20 | +2.37% | 4.63M | 28/03 | ||
BP | 495.70 | 498.75 | 493.30 | +2.90 | +0.59% | 35.58M | 28/03 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review